Live Breaking News & Updates on Accutar biotechnology

Stay informed with the latest breaking news from Accutar biotechnology on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Accutar biotechnology and stay connected to the pulse of your community

Evommune and Accutar Collaborate on AI-based Drug Discovery

Evommune and Accutar Collaborate on AI-based Drug Discovery
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

Jeegar-patel , Accutar-biotechnology , Jie-fan ,

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Accutar-biotechnology-inc , Chimeric-degrader-with , Differentiated-mechanism , Removing-both-kinase-and-scaffolding-functions , Coverage-designed , Overcome-resistance , Covalent-and-non , Accutar-biotechnology , Tyrosine-kinase , Jie-fan , Chief-executive-officer

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jiaqi-ren , Accutar-biotechnology-inc , Chimeric-degrader-with , Differentiated-mechanism , Removing-both-kinase-and-scaffolding-functions , Coverage-designed , Overcome-resistance , Covalent-and-non , Tyrosine-kinase , Jie-fan , Chief-executive-officer

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Accutar-biotechnology-inc , Chimeric-degrader-with , Differentiated-mechanism , Removing-both-kinase-and-scaffolding-functions , Coverage-designed , Overcome-resistance , Covalent-and-non , Tyrosine-kinase , Jie-fan , Chief-executive-officer , Accutar-biotechnology

Clinical Trial: AC699 in ER+, HER2- Advanced Breast Cancer

Researchers are conducting a phase 1 trial to test AC699 in patients with ER+, HER2- locally advanced or metastatic breast cancer.

Accutar-biotechnology-inc , Accutar-biotechnology ,

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-ce

CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment o...

Accutar-biotechnology-inc , Drug-administration , Accutar-biotechnology , Tyrosine-kinase , Jie-fan , Chief-executive-officer ,

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Accutar-biotechnology-inc , Drug-administration , Tyrosine-kinase , Jie-fan , Chief-executive-officer , Accutar-biotechnology ,

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Accutar-biotechnology-inc , Drug-administration , Accutar-biotechnology , Tyrosine-kinase , Jie-fan , Chief-executive-officer ,

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Posi

CRANBURY, N.J. & SHANGHAI--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, announces the dosing of the first patient in China in a Phase 1 study of AC0682, an orally bioavailable chimeric degrader molecule designe...

China , Shanghai , Chinese , China-national-medical-products-administration , Accutar-biotechnology-inc , Accutar-biotechnology , Jie-fan , Chief-executive-officer ,

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Accutar-biotechnology-inc , Drug-administration , Fast-track , Jie-fan , Chief-executive-officer , Accutar-biotechnology , Metastatic-castration-resistant-prostate-cancer ,